European Companies Search Engine

Quick Search Power Search
Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

Adverio Pharma GmbH, Leverkusen, Germany

Watch

If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company.

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Dossier

The dossier is a printable PDF file, summarizing information and publications for this company. The creation of dossiers is included in your subscription. After the creation of the dossier is completed, it will be sent to your email address .

Add to dossier (if available):

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Name

Adverio Pharma GmbH

Register

Ut
District Court of Cologne HRB 103180
Ut
District Court of Cottbus HRB 11692
Lei
549300U3IC9UCOLHS234

Address

Kaiser-Wilhelm-Allee 1, 51373 Leverkusen, Germany
Schönefeld, Germany

Corporate purpose

The preservation and administration of intellectual property, in particular industrial property rights such as patents, trademarks, utility models, designs and know-how as well as their commercial exploitation within the framework of existing or to be concluded cooperations with third parties worldwide in the pharmaceutical industry.

Financials

History

Legal Representatives

Marketing & Tech

Network

Loading network

JOBS AT NORTH DATA

  • Modern Java Developer

Publications

11 Apr 2022
Managing Director: Markus Albers · No longer Managing Director: Andreas Nauck
18 Jan 2022
Original document: “Liste der Gesellschafter“
28 Dec 2021
No longer Officer (1)
10 Nov 2021
Officer: Gregor Ch. Schwartze
23 Jun 2021 via Bayer AG, also 22/05/2019, 22/05/2019, 25/04/2018, 16/04/2018, 17/05/2017, 22/04/2016, 21/04/2015
Shareholder: Bayer AG
15 Jun 2021
Patent: Process for Preparing Methyl {4,6-Diamino-2-[5-Fluoro-1-(2-Fluorobenzyl)-1H-Pyrazolo[3,4-B]Pyridin-3-YL]Pyrimidin-5-YL}Carbamate
2 Feb 2021
Patent: Nanoformulations of Methyl {4,6-Diamino-2-[5-Fluoro-1-(2-Fluorobenzyl)-1H-Pyrazolo[3,4-B]Pyridin-3-YL]Pyrimidin-5-YL}Carbamate
20 Jan 2021
Patent: Substituted 5-Fluoro-1H-Pyrazolopyridines in Crystalline Form
12 Nov 2020
No longer Officer: Thomas Bögner
13 Oct 2020
Change of headquarters: Adverio Pharma GmbH · Seat: Leverkusen, Germany
30 Sept 2020
MD: Andreas Nauck · PPA (3) · Control: Bayer Intellectual Property GmbH · Change of headquarters: Adverio Pharma GmbH · Address · Capital: €25,000 · Share­holder agreement · Proxy · Corporate Purpose
4 Sept 2020
Original document: “Gesellschaftsvertrag / Satzung / Statut“
15 Jul 2020
Patent: Forms of Methyl {4,6-Diamino-2-[1-(2-Fluorobenzyl)-1H-Pyrazolo[3,4-B]Pyridino-3-YL]Pyrimidino-5-YL}Methyl Carbamate
16 Jun 2020
Patent: Process for Preparing Methyl {4,6-Diamino-2-[5-Fluoro-1-(2-Fluorobenzyl)-1H-Pyrazolo[3,4-B]Pyridin-3-YL]Pyrimidin-5-YL}Carbamate
6 May 2020
Officer: Thomas Bögner · No longer Managing Director: Thomas Bögner
29 Feb 2020
Address
15 Jan 2020
Patent: Process for Manufacturing 4-(2,2,3,3-Tetrafluoropropyl)Morpholine
25 Dec 2019
Patent: Method for the Preparation of Methyl-{4,6-Diamino-2-[1-(2-Fluorobenzyl)-1H-Pyrazolo[3,4-B]Pyridin-3-YL]Pyrimidin-5-YL}Methylcarbamate
16 Dec 2019
Patent: Methyl {4,6-Diamino-2-[5-Fluoro-1-(2-Fluorobenzyl)-1H-Pyrazolo[3,4-B]Pyridin-3-YL]Pyrimidin-5-YL}Carbamate Active Compound Product Having Improved Properties, Production and Formulation …
4 Jun 2019
Share­holder agreement
28 May 2019
Patent: Method of Identifying a Subgroup of Patients Suffering From Dcssc Which Benefits From a Treatment with SGC Stimulators and SGC Activators in a Higher Degree Than a Control Group
2 Jan 2019
Patent: Substituted 5-fluorine-1H-pyrazolopyridine in crystalline form
19 Dec 2018
Patent: Process for the preparation of methyl-4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-B]pyridine-3-YL]pyrimidine-5-YL-methylcarbalate
4 Dec 2018
Managing Director: Andreas Nauck · No longer Managing Director: Franz Kunisch
1 Aug 2018
Patent: Method for Producing Substituted 5-Fluoro-1H-Pyrazolopyridines
1 Aug 2018
Patent: Process for the Preparation of Methyl-{4,6-Diamino-2-[1-(2-Fluorobenzyl)-1H-Pyrazolo[3,4-b]Pyridin-3-yl]Pyrimidin-5-yl}Methylcarbamate for use as Pharmaceutically Active Ingredient
11 Jun 2018
Patent: SGC Stimulators and SGC Activators for USE in Preventing or Delaying Disease Progression or Stabilizing Disease in Patients Suffering From Diffuse Cutaneous Systemic Sclerosis (Dcssc)
20 Dec 2017
Managing Director: Thomas Bögner · No longer Managing Director: Detlev Hessenbruch
5 Oct 2016
Patent: Method for Producing Substituted (Z)-Alpha-Fluoro-Beta-Amino-Acrylaldehydes
27 Jan 2016
Patent: Substituted 5-Fluoro-1H-Pyrazolopyridines and USE Thereof
7 Oct 2015
Patent: Method for Producing Methyl- {4,6-Diamino-2-[1-(2-Fluorobenzyl) -1H-Pyrazolo[3,4-b]Pyridin-3-yl]-Pyrimidin-5-yl}-Methyl Carbamate and its Purification for its use as a Pharmaceutical Agent
12 Aug 2015
Patent: sGC Stimulators or sGC Activators Alone and in Combination with PDE5 Inhbitors for the Treatment of Cystic Fibrosis
22 Jul 2015
Patent: Process for the preparation of substituted (Z)-alpha-fluoro-beta-amino-acrylaldehyde
24 Jun 2015
Patent: The USE of sGC Stimulators, sGC Activators, Alone and Combinations with PDE5 Inhibitors for the Treatment of Systemic Sclerosis (SSc)
24 Dec 2014
Managing Director: Franz Kunisch
11 Nov 2014
Officer (2) · Control: Bayer Intellectual Property GmbH
1 Oct 2014
Patent: Process for the Purification of Methyl-{4,6-Diamino-2-[1-(2-Fluorobenzyl)-1H-Pyrazolo[3,4-B]Pyridin-3-YL]Pyrimidin-5-YL}Methylcarbamate
28 Aug 2014
Patent: Forms of 4,6-diamino-2-[1-(2-fluorobenyl)-1H-pyrazolo[3,4-B]pyridino-3-YL]Pyrimidino-5-YL-methylcarbalate
15 Aug 2014
Reg­is­tra­tion · Managing Director: Detlev Hessenbruch · Capital: €25,000 · Share­holder agreement · Legal form: GmbH · Proxy · Corporate Purpose

Mentions

14 Feb 2024
Direct parent: Bayer AG
14 Feb 2024
Ultimate parent: Bayer AG

The data on this page is generated by a fully automated algorithm. It may have errors, and is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.

Creative Commons License The visualizations for "Adverio Pharma GmbH, Leverkusen, Germany" are provided by North Data and may be reused under the terms of the Creative Commons CC-BY license.

Printing is only available to North Data premium service subscribers.
Close